| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Clinical Cancer Genetics and Human Cancer Genetics Programs, Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 [L-P. W., W. M. S., P. L. M. D., C. E.]; Charles A. Dana Human Cancer Genetics Unit, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 [P. L. M. D.]; Department of Biology, Cancer Research Center, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [U. Z., E. G., J. A. L.]; and CRC Human Cancer Genetics Research Group, University of Cambridge, Cambridge UK CB2 2QQ, United Kingdom [C. E.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
PTEN is a dual specificity phosphatase, i.e., it possesses phosphatase activity on phosphotyrosyl and phosphoseryl/threonyl residues. It appears to be a major phosphatase in the PI3K pathway, acting as the phosphatidylinositol 3-phosphatase (8 , 12) . PTEN has been shown to be implicated in cell migration and spreading through interaction with focal adhesion kinase (13) and in cell growth suppression through inhibition of PI3K/Akt-mediated signal transduction (8 , 14, 15, 16) . Several studies (14 , 16 , 17) have shown that transient introduction of PTEN into PTEN-null glioma cell lines causes cell cycle arrest at the G1 phase but not apoptosis (16 , 18) . In contrast, one group reported that transient expression of PTEN by adenoviral DNA delivery into breast cancer cell lines induces apoptosis but not cell cycle arrest (15) . Hence, it is still unclear whether PTEN plays distinct tissue-specific roles, i.e., only apoptosis in breast cancer cells versus G1 arrest in glioma cells. A number of "gatekeeper" tumor suppressors, such as p53 (19) , RB (20) , and APC (21 , 22) , are involved in the regulation of both cell cycle progression and cell death. Whether the tumor suppressor PTEN could function through regulating both the cell cycle and cell death in the same cell type is unclear. Therefore, we sought to determine whether PTEN could indeed mediate both the cell cycle and cell death and whether one is dependent on the other in the context of breast cancer, the major component cancer of CS, by using a Tet-inducible stable transfection system. Furthermore, we chose MCF-7, a breast cancer cell with endogenous wild-type functional PTEN, so that when mutant constructs are transfected, it would mimic the in vivo human situation; CS mutations are heterozygous, and the great majority of CS and primary sporadic breast tumors do not have biallelic PTEN mutations (23) .
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Plasmid Construction and Transfection.
The PTEN cDNA was obtained by PCR using the normal human thyroid cDNA as template and the following primers: 5'-CATCTCTCTCCTCCTTTTTCTTCA and 5'-TTTTCATGTGTTTTATCCCTCTT, which span the entire coding region of PTEN (27)
. The resulting PCR product was cloned into pCR2.1 vector. The inducible mammalian cell expression vector pUHD10-3 (24
, 25)
, which contains a Tet-suppressible (Tet-off) promoter, was used to generate two sets of PTEN expression constructs. The wild-type PTEN cDNA, including full-length PTEN coding sequence, was cloned into pUHD10-3 to generate pUHD10-3/PTEN.WT. The conserved cysteine residue at codon 124 was mutated to serine by PCR-based site-directed mutagenesis to generate phosphatase dead mutant pUHD10-3/PTEN.CS. The MCF-7/Toff cell line, which was stably transfected with the Tet-controlled transactivator expression plasmid pUHD15-1, was used to establish two sets of stable expression cell lines that can be induced to express wild-type PTEN, MCF-7/PTEN-wt, and phosphatase-dead PTEN, MCF-7/PTEN-cs. Transfections were done using Lipofectamine (Life Technologies). Exponentially growing cells (5 x 104) were transfected with 1 µg of plasmid DNA on a 35-mm dish. The cells were transferred to p100-mm dishes 24 h after transfection and selected by puromycin (Sigma) at 1 µg/ml for 6 days. Tet (1 µg/ml) was included in the culture medium to silence the ectopic expression of PTEN during the process of cloning.
Induction of PTEN Expression.
Subconfluent stock cells were washed three times with medium, once with phosphate-buffered NaCl solution (150 mM NaCl, 1.35 mM KH2PO4, and 2.7 mM Na2HPO4, pH 7.2), and then trypsinized. Equal numbers of cells were plated into Tet-free culture medium to induce PTEN expression and into medium containing 1 µg/ml Tet as a control and cultured for various lengths of time as indicated in "Results."
Cell Growth Assay.
Cell growth was measured by methylene blue. Equal numbers of cells were plated into Tet+ and Tet- media in 12-well plates and cultured for various times. After incubation, medium was removed, and cells were washed with phosphate-buffered NaCl solution and fixed with 12.5% glutaraldehyde (Fisher, Fair Lawn, NJ) for 20 min at room temperature. Cells were rinsed with distilled water and incubated with 0.05% methylene blue (Sigma) for 30 min, again rinsed with water, and then incubated with 800 µl of 0.33 M HCl for 30 min to extract the methylene blue. Absorption was measured at 595 nm. The ratio of the absorption in Tet- cultures to the absorption in Tet+ cultures at each time point was calculated and presented as percentage of cell growth.
FACS Analysis.
Assays were performed in p100-mm dishes. At the end of incubation, cells were trypsinized and washed into ice-cold phosphate-buffered NaCl solution. Cells were then fixed by adding them dropwise into ice-cold 80% ethanol while vortexing, followed by incubation on ice for 60 min. The fixed cells were washed with cold phosphate-buffered NaCl solution and incubated at 37°C for 30 min in 0.5 ml phosphate-buffered NaCl solution containing 10 µg/ml of propidium iodine (Sigma) and 5 µg/ml RNase A (New England Biolab, Beverly, MA). DNA content was determined by FACS scan analysis (Becton Dickinson).
Cell Death Assay.
Dead cells were determined by trypan blue staining. Both floating cells and trypsinized attached cells were collected and incubated with 0.2% trypan blue for 5 min at room temperature. Blue cells and total cells were counted. Cell death was presented as percentage of blue cells versus total cells. Apoptotic cell death was confirmed by TUNEL assay. TUNEL analysis of DNA fragmentation was performed using an in situ apoptosis detection kit (ApopTag), following the procedures recommended by the manufacturer (Intergen, Purchase, NY).
Protein Extraction and Immunoblotting.
After PTEN induction, cells were washed twice with ice-cold phosphate-buffered NaCl solution and lysed in cold lysis buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5% NP40, 1 mM EDTA, 1 mM EGTA, 5 µM phenylmethylsulfonyl fluoride, 5 µg/ml of leupeptin, pepstatin A, and aprotinin, 1 mM Na3VO4, 2 mM NaF, and 2 mM Na4PO7] for 10 min on ice. Insoluble material was removed from cell lysates by centrifugation at 4°C. Protein concentration was calculated by Bradford reagent. The Bradford reagent and other chemicals were purchased from Sigma.
Cell lysates were mixed with equal volumes of 2x Laemmli sample buffer, boiled for 10 min, resolved by 10% SDS-PAGE, and transferred onto nitrocellulose membrane. The membranes were blocked with 5% nonfat dry milk in TBST (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, and 0.05% Tween 20) for 1 h at room temperature and then incubated with appropriate primary antibody for 2 h at room temperature or overnight at 4°C, followed by incubation with horseradish peroxidase-conjugated secondary antibody (Promega Corp., Madison, WI) at 1:5000 dilution for 1 h at room temperature. Protein signals were detected by enhanced chemiluminescence (Amersham, Piscataway, NJ).
For growth factor stimulation, cells were starved by exposure to serum free medium for 24 h before adding growth factors. Both insulin and EGF were purchased from Life Technologies, Inc. The anti-PTEN monoclonal antibody (26)
or polyclonal TB-166 (27)
was used at 1:250 or 1:1000 dilution, respectively. The polyclonal anti-phospho-Akt, anti-Akt, anti-phospho-MAPK, and anti-MAPK (New England Biolab, Boston, MA) were used at 1:1000 dilution, and monoclonal anti-
-tubulin (Sigma) was used at 1:5000 dilution.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Constructs expressing either wild-type PTEN or a phosphatase-dead mutant, C124S, under the control of the Tet-off promoter were transfected into MCF-7/Toff cells. Stable clones, which could be induced to express either wild-type PTEN or mutant PTEN protein, were generated and screened for PTEN expression by Western blot using anti-PTEN antibody (Fig. 1)
. In general, comparable amounts of PTEN protein were induced in the two sets of transfectants (Fig. 1A)
. Depending on the individual clone, anywhere from <1-fold to 
4-fold increased expression of PTEN, compared with control levels, could be induced. PTEN protein levels of all clones growing in the presence of Tet was indistinguishable from the endogenous level of MCF-7/Toff cells, indicating that there is no leaky activity of the Tet-off promoter in this cell line. The increase in PTEN protein expression appeared at 8 h and reached its maximum level at 36 h after withdrawing Tet (Fig. 1B)
. Furthermore, the level of PTEN induction could be finely controlled by the concentration of Tet (Fig. 1C)
. A concentration of Tet as low as 10 ng/ml is sufficient to suppress PTEN expression.
|
PTEN Suppresses Cell Growth.
To investigate whether increased levels of either wild-type PTEN or phosphatase-dead mutant PTEN in MCF-7 had effects on growth properties, we induced both wild-type and mutant PTEN expression over a time course. Parental MCF-7/Toff, MCF-7/PTEN-wt, and MCF-7/PTEN-cs cells were seeded at equal density and cultured in the presence or absence of Tet. The number of cells after culture at each time point was determined by methylene blue staining, and the ratio of the number of cells in Tet- cultures to the number in the Tet+ cultures was calculated. After 48 h induction, the cell number of MCF-7/PTEN-wt grown in the absence of Tet started to decrease, and at 120 h, reached 50% of the cell number compared with that of MCF-7/PTEN-wt grown in the presence of Tet (Fig. 2)
. The phosphatase-dead mutant carries the C124S mutation described in the germ-line of CS patients (30)
. It has been shown that this substitution completely abrogates PTEN phosphatase activity (18)
. In contrast to overexpression of wild-type PTEN, overexpressing the C124S mutant in MCF-7 cells did not alter cell growth over time, indicating that growth suppression by PTEN is mediated through its phosphatase activity.
|
, the induction of PTEN expression resulted in a significant increase in the numbers of cells at G1 and decrease in the number of cells at S phase. The number of cells at G1 increased from 52.1% (MCF-7/PTEN-wt, Tet+) to 68.6% (MCF-7/PTEN-wt, Tet-), and the number of cells at S decreased from 31.0 to 19.5%. No significant changes in cell cycle distribution were observed in MCF-7/PTEN-cs cells, suggesting that the phosphatase activity was required for PTEN-mediated G1 arrest. Tet alone had no effect on cell cycle distribution in MCF-7 cells.
|
demonstrated that a significant increase in the number of cells in G1 phase began at 36 h of PTEN induction, 12 h before the reduction in cell number (Fig. 2)
. Interestingly, no cell death could be detected at the 72-h induction time (Fig. 4)
, suggesting that the mechanism of growth suppression mediated through PTEN in MCF-7 cells was G1 arrest, at least, until this time point.
|
. In contrast, >3-fold increased dead cells (from 5.5 to 17.5%) were noted in the MCF-7/PTEN-wt-transfected line but not in the MCF-7/PTEN-cs-transfected line after 120 h induction (Fig. 4)
. Thus, it would appear that PTEN exerts cell growth suppression through both cell cycle blockade and cell death in MCF-7 cells in a sequential manner; G1 arrest appeared first, followed by cell death. The cell death induced by overexpressing PTEN was apoptotic cell death, as confirmed by TUNEL assay (Fig. 4B)
. The difference of the percentage of cell death detected by TUNEL assay was similar to that detected by trypan blue staining.
Negative Regulation of PI-3K/AKT Pathway by PTEN.
PI3K has been implicated in transducing both proliferation and survival signals (31
, 32)
. It has been shown both in vivo and in vitro that the products of PI3K are the substrates of PTEN (8
, 12)
. The full activation of Akt requires the binding of phosphatidylinositol-(3,4)-biphosphates and subsequential phosphorylation on Ser-473 and on Thr-308. To determine whether PTEN effected the downstream signaling of PI3K, we analyzed the phosphorylation status of Akt, one of the well-characterized downstream targets of PI3K, in wild-type and mutant overexpressing cells by Western blot using an antibody specific to phospho-Ser-473. In the MCF-7/PTEN-wt cells, a substantial reduction in the amount of phosphorylated Akt was apparent, in contrast to that observed in the MCF-7/PTEN-cs cells (Fig. 5A)
. The levels of total Akt remained unchanged, as revealed by Western blot using antibody recognizing both phosphorylated and unphosphorylated forms; therefore, the decreased signal in phosphorylated Akt was attributable to phosphorylation. Overexpression of PTEN caused a partial block of Akt phosphorylation in response to the stimulation of insulin and epithelial growth factor (Fig. 5C)
, two potent stimulators of the PI3K pathway. In this instance, the partial block was not attributable to the insufficient induction of PTEN expression under these experimental conditions, because the consistently increased levels of PTEN were noted by Western blot. The effect of PTEN on Akt phosphorylation appeared to be specific because MAPK phosphorylation was not affected by overexpression of PTEN under the same conditions (Fig. 5C)
.
|
. A clear decrease in the amount of phosphorylated Akt appeared at 24 h of PTEN induction and remained low thereafter. Note that the accumulation of cells at G1 in PTEN-wt cells occurred at 36 h after withdrawing Tet. The appearance of Akt hypophosphorylation before G1 arrest would suggest that Akt underphosphorylation could be the direct cause of G1 arrest.
To determine the correlation of Akt phosphorylation with the endogenous level of PTEN in breast cancer, we examined the PTEN protein and Akt phosphorylation in a panel of 10 breast cancer cell lines with known PTEN gene status. Three lines, BT-549, MDA-MB-468, and ZR-75-1, have one allele deleted; they also have mutations in their respective second alleles, a 44-bp deletion within exon 6, a 2-bp insertion within exon 4, and missense mutation L108R.4
No mutation or deletion of the coding regions in the other seven lines has been noted. In general, lines with structurally abnormal PTEN have no PTEN protein. However, it should be noted that MDA-MB-436 and MDA-MB-435S, without genomic PTEN abnormalities, had no PTEN or low levels of PTEN protein. An inverse correlation of PTEN with Akt phosphorylation appeared in 9 of the 10 lines (Fig. 5D)
. Three lines (BT-549, MAD-MB-436, and MAD-MB-468) with no detectable PTEN and one line (ZR-75-1) with very low levels of PTEN had high levels of phosphorylated Akt. Five lines with relatively high levels of PTEN (MDA-MB-435, BT-20, T47-D, MDA-MB-231, and MCF-7) had low levels of phosphorylated Akt. The exception to the inverse correlation rule was seen in HS-578T; it had high levels of phosphorylated Akt and high levels of PTEN.
Inhibition of PI-3K Leads to G1 Arrest and Cell Death.
To further investigate whether the effects of PTEN on both cell growth and cell death in the MCF-7 breast cancer cell line were mediated by blocking PI3K signaling, we analyzed the cell cycle and cell death in MCF-7 cells treated with wortmannin, a specific inhibitor of PI3K. Treatment of MCF-7 cells with wortmannin at 200 n for 72 h led to a 40% reduction in cell number (Fig. 6A)
. If the cells were treated with wortmannin for only 24 h, the number of G1 phase cells increased (Fig. 6B)
, and the number of dead cells remained unchanged (Fig. 6C)
. A significantly increased number of dead cells was detected after 72 h of wortmannin treatment (Fig. 6C)
. These results are consistent with the growth suppressive action of PTEN on this cell line. At a concentration of 200 nM, wortmannin sufficiently inhibited PI3K activity, and the effects were sustained for 24 h, as judged by levels of Akt phosphorylation (Fig. 5C
and Fig. 6D
). The similarity of growth inhibition and mechanism of action between overexpression of PTEN and treatment with a specific inhibitor of PI3K provided additional evidence that PTEN inhibits cell growth in a breast cancer cells by blocking the PI3K signal transduction pathway, which in turn leads to G1 cell cycle arrest and sequential cell death.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Our data clearly showed that exogenous wild-type PTEN inhibits cell cycle progression in MCF-7 breast cancer cell line, and others have reported that reintroduction of wild-type PTEN blocks cell cycle progression in glioma (14 , 16 , 33) . An increase in cell proliferation throughout the premorbid embryo, particularly in the ectoderm region, has been shown in pten-deficient mice. Those data suggest that PTEN may play an universal role in regulation of cell cycle. The role of PTEN in the regulation of apoptosis is intriguing. It is clear from our results and those of Li et al. (15) that exogenous wild-type PTEN induces apoptosis in breast cancer cell lines, but exogenous expression of wild-type PTEN in glioma results in G1 cell cycle arrest without cell death (16 , 18) . Another contrasting point is the previous observation that exogenous PTEN transiently transfected into cells with both wild-type copies of PTEN did not alter growth characteristics (33 , 40 , 41) . Our data obtained from a stable expressing system clearly show that ectopic expression of PTEN in PTEN wild-type MCF-7 cells clearly can produce an effect on cell growth characteristics, and Li et al. (15) has shown that exogenous PTEN inhibits cell growth regardless of endogenous PTEN status. These discrepancies may be attributable to the differences of PTEN signaling between breast epithelial and other cell types.
Although it is clear from our data and previous data that growth suppression of PTEN in cancer cell line models and in vivo neoplasia is mediated by blocking the PI3K signaling pathway, it is becoming obvious that the precise response of a cell and the panoply of pathways downstream of Akt is not straightforward. PI-3K has been implicated in transducing both proliferation and survival signals. On the one hand, it is required for G1 to S phase progression stimulated by a variety of growth factors (42) ; it is involved in up-regulation of cyclin D expression in NIH 3T3 fibroblasts and the MCF-7 breast cancer line (43) , and it is involved in down-regulation of p27KIP1 in NIH 3T3 fibroblasts and smooth muscle cells (44) and activation of p70s6k, which regulates a subset of mRNA species thought to be important for cell cycle progression (45 , 46) . On the other hand, recent reports reveal that activation of PI3K or Akt protects various cell types from apoptosis induced by withdrawing survival factors (32 , 35, 36, 37, 38, 39) , induces the expression of antiapoptotic Bcl-2 (47) , and phosphorylates and inactivates the proapoptotic Bcl-2 family member BAD (35) , as well as phosphorylates and inhibits the Forkhead family of transcription factors, which can induce the expression of genes critical for cell death, such as the FAS ligand (48) .
It has been shown that PTEN interacts and dephosphorylates focal adhesion kinase, which is involved in the regulation of cell growth and apoptosis (49) through transducing cell adhesion-mediated signaling. Although the data from our laboratory and others support that the growth inhibition of PTEN is mediated through its lipid phosphatase activity, it is still not clear yet whether the protein phosphatase activity also participates in the regulation of cell growth in synergistic way with its lipid phosphatase activity. Some naturally occurring mutations, such as G129E, which retain protein phosphatase activity but lose lipid phosphatase activity, could be useful tools to help answer this question.
Cell growth requires both proliferation signals and survival signals. Tumor cells gain a growth advantage by abnormal proliferation and a defect in the regulation of cell death. A handful of tumor suppressors including p53 (19) , RB (20) , BRCA1 (50 , 51) , and APC (21 , 22) exert direct effects both on cell cycle progression and cell viability. Our results and those of others do indeed suggest that PTEN participates in the regulation of cell proliferation and cell survival like p53 and RB, the well known "gatekeeper" tumor suppressor.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 This research was partially funded by Grants PRG-97-064-01 and RPG-98-211-01-CCE from the American Cancer Society, Contract DAMD17-98-1-8058 from the United States Army Breast Cancer Research Program, a grant from the Concert for the Cure (to C. E.), and Grant P30 CA16058 from the National Cancer Institute (to the Ohio State University Comprehensive Cancer Center). P. L. M. D. is a recipient of a Susan G. Komen Postdoctoral Research Fellowship (to C. E.). 
2 To whom requests for reprints should be addressed, at Human Cancer Genetics Program, Ohio State University, 420 West 12th Avenue, Room 690C MRF, Columbus, OH 43210. Phone: (614) 688-4508; Fax: (614) 688-3582 or (614) 688-4245; E-mail: eng-1{at}medctr.osu.edu
3 The abbreviations used are: PTEN, phosphatase and tensin homolog, deleted on chromosome 10; MMAC, mutated in multiple advanced cancers; TEP1, transforming growth factor 
-regulated and epithelial cell-enriched phosphatase; CS, Cowden syndrome; EGF, epidermal growth factor; FACS, fluorescence-activated cell sorting; PI3K, phosphatidylinositol 3-kinase; TUNEL, terminal deoxynucleotidyl transferase-mediated nick end labeling; MAPK, mitogen-activated protein kinase; Tet, tetracycline; wt, wild type.
4 L-P. Weng and C. Eng, unpublished observations.
Received 5/21/99. Accepted 9/22/99.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  C. Martin-Fernandez, J. Bales, C. Hodgkinson, A. Welman, M. J. Welham, C. Dive, and C. J. Morrow Blocking Phosphoinositide 3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but Does Not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs Mol. Cancer Res., June 1, 2009; 7(6): 955 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Fournier, J. E. Fata, K. J. Martin, P. Yaswen, and M. J. Bissell Interaction of E-cadherin and PTEN Regulates Morphogenesis and Growth Arrest in Human Mammary Epithelial Cells Cancer Res., May 15, 2009; 69(10): 4545 - 4552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Woiwode, S. A. S. Johnson, S. Zhong, C. Zhang, R. G. Roeder, M. Teichmann, and D. L. Johnson PTEN Represses RNA Polymerase III-Dependent Transcription by Targeting the TFIIIB Complex Mol. Cell. Biol., June 15, 2008; 28(12): 4204 - 4214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Aalinkeel, Z. Hu, B. B. Nair, D. E. Sykes, J. L. Reynolds, S. D. Mahajan, and S. A. Schwartz Genomic Analysis Highlights the Role of the JAK-STAT Signaling in the Anti-proliferative Effects of Dietary Flavonoid 'Ashwagandha' in Prostate Cancer Cells Evid. Based Complement. Altern. Med., January 10, 2008; (2008) nem184v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Adachi, S. Hanaka, T. Masuda, H. Yoshihara, H. Nagase, and K. Ohta Transduction of Phosphatase and Tensin Homolog Deleted on Chromosome 10 into Eosinophils Attenuates Survival, Chemotaxis, and Airway Inflammation J. Immunol., December 15, 2007; 179(12): 8105 - 8111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Selvendiran, L. Tong, S. Vishwanath, A. Bratasz, N. J. Trigg, V. K. Kutala, K. Hideg, and P. Kuppusamy EF24 Induces G2/M Arrest and Apoptosis in Cisplatin-resistant Human Ovarian Cancer Cells by Increasing PTEN Expression J. Biol. Chem., September 28, 2007; 282(39): 28609 - 28618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Marino, N. Salvador-Montoliu, A. Fueyo, E. Knecht, N. Mizushima, and C. Lopez-Otin Tissue-specific Autophagy Alterations and Increased Tumorigenesis in Mice Deficient in Atg4C/Autophagin-3 J. Biol. Chem., June 22, 2007; 282(25): 18573 - 18583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Alvarez-Breckenridge, K. A. Waite, and C. Eng PTEN regulates phospholipase D and phospholipase C Hum. Mol. Genet., May 15, 2007; 16(10): 1157 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hou, D. Liu, Y. Shan, S. Hu, K. Studeman, S. Condouris, Y. Wang, A. Trink, A. K. El-Naggar, G. Tallini, et al. Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1161 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Minaguchi, K. A. Waite, and C. Eng Nuclear Localization of PTEN Is Regulated by Ca2+ through a Tyrosil Phosphorylation-Independent Conformational Modification in Major Vault Protein Cancer Res., December 15, 2006; 66(24): 11677 - 11682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Chung, M. C. Ostrowski, T. Romigh, T. Minaguchi, K. A. Waite, and C. Eng The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation Hum. Mol. Genet., September 1, 2006; 15(17): 2553 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Agrawal and C. Eng Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer Hum. Mol. Genet., March 1, 2006; 15(5): 777 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Edwin, R. Singh, R. Endersby, S. J. Baker, and T. B. Patel The Tumor Suppressor PTEN Is Necessary for Human Sprouty 2-mediated Inhibition of Cell Proliferation J. Biol. Chem., February 24, 2006; 281(8): 4816 - 4822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Chung and C. Eng Nuclear-Cytoplasmic Partitioning of Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) Differentially Regulates the Cell Cycle and Apoptosis Cancer Res., September 15, 2005; 65(18): 8096 - 8100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang, L. Comai, and D. L. Johnson PTEN Represses RNA Polymerase I Transcription by Disrupting the SL1 Complex Mol. Cell. Biol., August 15, 2005; 25(16): 6899 - 6911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Agrawal, R. Pilarski, and C. Eng Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN Hum. Mol. Genet., August 15, 2005; 14(16): 2459 - 2468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Liu, X. Sheng, Z. K. Hortobagyi, Z. Mao, G. E. Gallick, and W. K. A. Yung Nuclear PTEN-Mediated Growth Suppression Is Independent of Akt Down-Regulation Mol. Cell. Biol., July 15, 2005; 25(14): 6211 - 6224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Chung, M. E. Ginn-Pease, and C. Eng Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) Has Nuclear Localization Signal-Like Sequences for Nuclear Import Mediated by Major Vault Protein Cancer Res., May 15, 2005; 65(10): 4108 - 4116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Oh, H.-J. List, R. Reiter, A. Mani, Y. Zhang, E. Gehan, A. Wellstein, and A. T. Riegel The Nuclear Receptor Coactivator AIB1 Mediates Insulin-like Growth Factor I-induced Phenotypic Changes in Human Breast Cancer Cells Cancer Res., November 15, 2004; 64(22): 8299 - 8308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tell, A. Pines, F. Arturi, L. Cesaratto, E. Adamson, C. Puppin, I. Presta, D. Russo, S. Filetti, and G. Damante Control of Phosphatase and Tensin Homolog (PTEN) Gene Expression in Normal and Neoplastic Thyroid Cells Endocrinology, October 1, 2004; 145(10): 4660 - 4666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mahimainathan and G. G. Choudhury Inactivation of Platelet-derived Growth Factor Receptor by the Tumor Suppressor PTEN Provides a Novel Mechanism of Action of the Phosphatase J. Biol. Chem., April 9, 2004; 279(15): 15258 - 15268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Nair, K. V. K. Rao, R. Aalinkeel, S. Mahajan, R. Chawda, and S. A. Schwartz Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes Clin. Vaccine Immunol., January 1, 2004; 11(1): 63 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-B. She, D. Solit, A. Basso, and M. M. Moasser Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3'-Kinase/Akt Pathway Signaling Clin. Cancer Res., October 1, 2003; 9(12): 4340 - 4346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Baker, G. Wei, A. E. Schaffner, and M. C. Ostrowski Ets-2 and Components of Mammalian SWI/SNF Form a Repressor Complex That Negatively Regulates the BRCA1 Promoter J. Biol. Chem., May 9, 2003; 278(20): 17876 - 17884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Waite and C. Eng BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels Hum. Mol. Genet., March 15, 2003; 12(6): 679 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Ginn-Pease and C. Eng Increased Nuclear Phosphatase and Tensin Homologue Deleted on Chromosome 10 Is Associated with G0-G1 in MCF-7 Cells Cancer Res., January 15, 2003; 63(2): 282 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-P. Zhou, A. Loukola, R. Salovaara, M. Nystrom-Lahti, P. Peltomaki, A. de la Chapelle, L. A. Aaltonen, and C. Eng PTEN Mutational Spectra, Expression Levels, and Subcellular Localization in Microsatellite Stable and Unstable Colorectal Cancers Am. J. Pathol., August 1, 2002; 161(2): 439 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-P. Weng, J. L. Brown, K. M. Baker, M. C. Ostrowski, and C. Eng PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway Hum. Mol. Genet., July 15, 2002; 11(15): 1687 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Varma and S. E. Conrad Antiestrogen ICI 182,780 Decreases Proliferation of Insulin-like Growth Factor I (IGF-I)-treated MCF-7 Cells without Inhibiting IGF-I Signaling Cancer Res., July 15, 2002; 62(14): 3985 - 3991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Xu, D. Stokoe, L. P. Kane, and A. Weiss The Inducible Expression of the Tumor Suppressor Gene PTEN Promotes Apoptosis and Decreases Cell Size by Inhibiting the PI3K/Akt Pathway in Jurkat T Cells Cell Growth Differ., July 1, 2002; 13(7): 285 - 296. [Abstract] [Full Text]
|
|
|
|
|
|
M. Fernandez and C. Eng The Expanding Role of PTEN in Neoplasia: A Molecule for All Seasons? : Commentary re: M. A. Davies, et al., Adenoviral-mediated Expression of MMAC/PTEN Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells. Clin. Cancer Res., 8: 1904-1914, 2002. Clin. Cancer Res., June 1, 2002; 8(6): 1695 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Davies, S. J. Kim, N. U. Parikh, Z. Dong, C. D. Bucana, and G. E. Gallick Adenoviral-mediated Expression of MMAC/PTEN Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Clin. Cancer Res., June 1, 2002; 8(6): 1904 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-P. Zhou, H. Hampel, J. Roggenbuck, N. Saba, T. W. Prior, and C. Eng A 39-bp Deletion Polymorphism in PTEN in African American Individuals: Implications for Molecular Diagnostic Testing J. Mol. Diagn., May 1, 2002; 4(2): 114 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Huang and C. D. Kontos PTEN Modulates Vascular Endothelial Growth Factor-Mediated Signaling and Angiogenic Effects J. Biol. Chem., March 22, 2002; 277(13): 10760 - 10766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-P. Zhou, S. Kuismanen, M. Nystrom-Lahti, P. Peltomaki, and C. Eng Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors Hum. Mol. Genet., February 1, 2002; 11(4): 445 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Liu, S. L. Asa, I. G. Fantus, P. G. Walfish, and S. Ezzat Vitamin D Arrests Thyroid Carcinoma Cell Growth and Induces p27 Dephosphorylation and Accumulation through PTEN/Akt-Dependent and -Independent Pathways Am. J. Pathol., February 1, 2002; 160(2): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. DiRenzo, S. Signoretti, N. Nakamura, R. Rivera-Gonzalez, W. Sellers, M. Loda, and M. Brown Growth Factor Requirements and Basal Phenotype of an Immortalized Mammary Epithelial Cell Line Cancer Res., January 1, 2002; 62(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Simpson, J. Li, D. Liaw, I. Hennessy, J. Oliner, F. Christians, and R. Parsons PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2 Mol. Cell. Biol., June 15, 2001; 21(12): 3947 - 3958. [Abstract] [Full Text]
|
|
|
|
|
|
X. Zhu, C.-H. Kwon, P. W. Schlosshauer, L. H. Ellenson, and S. J. Baker PTEN Induces G1 Cell Cycle Arrest and Decreases Cyclin D3 Levels in Endometrial Carcinoma Cells Cancer Res., June 1, 2001; 61(11): 4569 - 4575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Mutter PTEN, a Protean Tumor Suppressor Am. J. Pathol., June 1, 2001; 158(6): 1895 - 1898. [Full Text] [PDF]
|
|
|
|
|
|
K. Kurose, X.-P. Zhou, T. Araki, S. A. Cannistra, E. R. Maher, and C. Eng Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas Am. J. Pathol., June 1, 2001; 158(6): 2097 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-i. Hisatake, J. O'Kelly, M. R. Uskokovic, S. Tomoyasu, and H. P. Koeffler Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells Blood, April 15, 2001; 97(8): 2427 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hutchinson, J. Jin, R. D. Cardiff, J. R. Woodgett, and W. J. Muller Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical Cell Survival Signal Required for Tumor Progression Mol. Cell. Biol., March 15, 2001; 21(6): 2203 - 2212. [Abstract] [Full Text]
|
|
|
|
|
|
L.-P. Weng, J. L. Brown, and C. Eng PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model Hum. Mol. Genet., March 1, 2001; 10(6): 599 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-P. Weng, W. M. Smith, J. L. Brown, and C. Eng PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model Hum. Mol. Genet., March 1, 2001; 10(6): 605 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-P. Weng, J. L. Brown, and C. Eng PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways Hum. Mol. Genet., February 1, 2001; 10(3): 237 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-P. Weng, O. Gimm, J. B. Kum, W. M. Smith, X.-P. Zhou, D. Wynford-Thomas, G. Leone, and C. Eng Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death Hum. Mol. Genet., February 1, 2001; 10(3): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Eng Will the real Cowden syndrome please stand up: revised diagnostic criteria J. Med. Genet., November 1, 2000; 37(11): 828 - 830. [Full Text]
|
|
|
|
|
|
A. Perren, P. Komminoth, P. Saremaslani, C. Matter, S. Feurer, J. A. Lees, P. U. Heitz, and C. Eng Mutation and Expression Analyses Reveal Differential Subcellular Compartmentalization of PTEN in Endocrine Pancreatic Tumors Compared to Normal Islet Cells Am. J. Pathol., October 1, 2000; 157(4): 1097 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-P. Zhou, O. Gimm, H. Hampel, T. Niemann, M. J. Walker, and C. Eng Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation Am. J. Pathol., October 1, 2000; 157(4): 1123 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Jung, J. Haendeler, C. Goebel, A. M. Zeiher, and S. Dimmeler Growth factor-induced phosphoinositide 3-OH kinase/Akt phosphorylation in smooth muscle cells: induction of cell proliferation and inhibition of cell death Cardiovasc Res, October 1, 2000; 48(1): 148 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gimm, T. Attie-Bitach, J. A. Lees, M. Vekemans, and C. Eng Expression of the PTEN tumour suppressor protein during human development Hum. Mol. Genet., July 1, 2000; 9(11): 1633 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Stambolic, M.-S. Tsao, D. Macpherson, A. Suzuki, W. B. Chapman, and T. W. Mak High Incidence of Breast and Endometrial Neoplasia Resembling Human Cowden Syndrome in pten+/- Mice Cancer Res., July 1, 2000; 60(13): 3605 - 3611. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. L. Mutter, M.-C. Lin, J. T. Fitzgerald, J. B. Kum, and C. Eng Changes in Endometrial PTEN Expression throughout the Human Menstrual Cycle J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2334 - 2338. [Abstract] [Full Text]
|
|
|
|
|
|
O. Gimm, A. Perren, L.-P. Weng, D. J. Marsh, J. J. Yeh, U. Ziebold, E. Gil, R. Hinze, L. Delbridge, J. A. Lees, et al. Differential Nuclear and Cytoplasmic Expression of PTEN in Normal Thyroid Tissue, and Benign and Malignant Epithelial Thyroid Tumors Am. J. Pathol., May 1, 2000; 156(5): 1693 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Arico, A. Petiot, C. Bauvy, P. F. Dubbelhuis, A. J. Meijer, P. Codogno, and E. Ogier-Denis The Tumor Suppressor PTEN Positively Regulates Macroautophagy by Inhibiting the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway J. Biol. Chem., September 14, 2001; 276(38): 35243 - 35246. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
), MCF-7/PTEN-wt (
), and MCF-7/PTEN-cs (
) cells. Each of the data points represents the mean of values from three separate experiments; bars, SD.
) or without (
) Tet for the indicated times. The indicated values are means of triplicate experiments; bars, SD.
) or without (
) Tet, and MCF-7/PTEN-cs with (
) or without (
) Tet are shown. The number of dead cells and total cells were counted and presented as a percentage of dead cells/total cells. The indicated values are means of triplicate dishes; bars, SD. B, characterization of PTEN-induced cell death. MCF-7/PTEN-wt cells were grown for 120 h with (left panel) or without (right panel) Tet. DNA fragmentation was detected by TUNEL assay (green), and propidium iodide (red) was used to counterstain nucleus. Apoptotic cells appear green or yellow because of double staining of green fluorescein and propidium iodide. Normal cells show only propidium iodide staining.
